Grapheal, a developer of graphene-based embedded biosensors for on-site diagnostics and remote patient monitoring, announced today that it has raised a total of EUR1.9 million in equity and non-dilutive sources, including seed financing from Novalis Biotech’s Acceleration Fund, several innovation grants, and Bpifrance convertible notes and loans.


Novalis Biotech (Ghent, Belgium) is an early stage venture capital investor in technologies that revolutionize healthcare. The company’s core competence lies in digitalization in the life sciences with a focus on bioinformatics, genomics and diagnostics. Novalis strongly believes in applying innovative enabling technology to advance the prevention, diagnosis, or treatment of a disease. Novalis Biotech Acceleration (Fund II) announced the first closing in November 2020.

Grapheal Raises EUR1.9 Million to Advance Development of Embedded Biosensing Technology and Application in Digital COVID Testing and Wound Monitoring

Description

Company Information

Grapheal Raises EUR1.9 Million to Advance Development of Embedded Biosensing Technology and Application in Digital COVID Testing and Wound Monitoring

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information